Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: An oasis of lipid-lowering therapies and a desert of reimbursement

This article was originally published in Scrip

Executive Summary

Last week was chock-full of commentary from the FDA Advisory Panels on the new lipid-lowering drugs directed against PCSK9 from Amgen and Sanofi/Regeneron Pharmaceuticals. Amongst those and other related companies, the only share price winner of the week was Sanofi, with its main listing outside of the US, and even then it was for the wrong reason.

You may also be interested in...



Stockwatch: Intercepting The Falling Knives Of NASH

A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.

Stockwatch: Age And Outcome Duration Cloud Innovative Therapy Reimbursement

Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.

Stockwatch: MonarchE And Tug-Of-War Drug Development

With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?

Topics

Related Companies

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel